# Immune history influences SARS-CoV-2 booster impacts: the role of efficacy and redundancy

# Sophie L. Larsen<sup>1</sup>, Iffat Noor<sup>2</sup>, Haylee West<sup>3</sup>, Eliana Chandra<sup>4,5</sup>, Pamela P. Martinez<sup>3,5,6\*</sup>, and Alicia N. M. Kraay<sup>2,6\*</sup>

<sup>1</sup>Program in Ecology, Evolution, and Conservation Biology, School of Integrative Biology, University of Illinois
 Urbana-Champaign, Urbana, IL, USA

<sup>7</sup> <sup>2</sup>Department of Kinesiology and Community Health, University of Illinois Urbana-Champaign, Champaign, IL, USA

<sup>3</sup>Department of Microbiology, School of Molecular and Cellular Biology, University of Illinois Urbana-Champaign, Urbana, IL, USA

<sup>4</sup>Department of Sociology, University of Illinois Urbana-Champaign, Champaign, IL, USA

<sup>5</sup>Department of Statistics, University of Illinois Urbana-Champaign, Urbana, IL, USA

<sup>12</sup> <sup>6</sup>Carl R. Woese Institute for Genomic Biology, University of Illinois Urbana-Champaign, Urbana, IL, USA

#### 13

8

9

10

11

#### Abstract

Given the continued emergence of SARS-CoV-2 variants of concern as well as unprecedented vac-14 cine development, it is crucial to understand the effect of the updated vaccine formulations at the popu-15 lation level. While bivalent formulations have higher efficacy in vaccine trials, translating these findings 16 to real-world effectiveness is challenging due to the diversity in immune history, especially in settings 17 with a high degree of natural immunity. Known socioeconomic disparities in key metrics such as vaccine 18 coverage, social distancing, and access to healthcare have likely shaped the development and distribu-19 tion of this immune landscape. Yet little has been done to investigate the impact of booster formulation 20 in the context of host heterogeneity. Using two complementary mathematical models that capture host 21 demographics and immune histories over time, we investigated the potential impacts of bivalent and 22 monovalent boosters in low- and middle-income countries (LMICs). These models allowed us to test 23 the role of natural immunity and cross-protection in determining the optimal booster strategy. Our re-24 sults show that to avert deaths from a new variant in populations with high immune history, it is more 25 important that a booster is implemented than which booster is implemented (bivalent vs. monovalent). 26 However, in populations with low preexisting immunity, bivalent boosters can become optimal. These 27 findings suggest that for many LMICs - where acquiring a new vaccine stock may be economically 28 prohibitive - monovalent boosters can still be implemented as long as pre-existing immunity is high. 29

<sup>30</sup> \* To whom correspondence should be addressed: pamelapm@illinois.edu and alicia.kraay@gatesfoundation.org

# 32 Introduction

<sup>33</sup> Host and pathogen heterogeneity are at the core of understanding infectious disease dynamics, including

the potential benefit of intervention strategies like the original SARS-CoV-2 monovalent and updated biva-

<sup>35</sup> lent booster vaccines. At the individual level, variation in behavior, viral shedding, and/or infectiousness

<sup>36</sup> can drive superspreading events across pathogens (e.g. [1, 2]). At the population level, host factors can

<sup>37</sup> also influence disease transmission. For instance, rent-to-income ratio and population density are associated

<sup>38</sup> with SARS-CoV-2 superspreading in Hong Kong, a so-called "double disadvantage" for impoverished indi-

viduals living in high-risk urban residential environments [3]. Lockdown mobility, testing, vaccination, and

<sup>40</sup> mortality during the SARS-CoV-2 pandemic have all been shown to be associated with socioeconomic status

41 (SES) [4–6]. Beyond the host, some pathogens evolve over time, with broad impacts on transmission poten-

tial. Rapid evolution observed for SARS-CoV-2 resulted in the emergence of several variants distinct from

the original wild-type virus, including Omicron. One early-pandemic estimate of the household secondary

attack rate for SARS-CoV-2 was placed at 18.9%, but later rose to 42.7% for Omicron cases [7].

It is crucial to understand the interactions of these pathogen and host factors cumulatively, through time. As 45 historical variants give way to their successors, experimental work with serological data has documented 46 substantial differences in immune response to SARS-CoV-2 variants and vaccination by variant-specific 47 immune history (e.g. [8–10]). This suggests the presence of an immune imprinting effect, where an individ-48 ual's prior exposure can impact the adaptive immune response to new infections [8, 11] - a phenomenon not 49 only observed for SARS-CoV-2, but also in other respiratory viruses such as influenza and SARS-CoV-1 50 (e.g. [12, 13]). This signature is also present in mouse models when immunizing sequentially with SARS-51 CoV-2 and SARS-CoV-1 or endemic coronaviruses [14, 15]. Despite these serological findings, the impacts 52 of SARS-CoV-2 imprinting at the population level are presently unknown. Given that host factors are known 53 to have influenced transmission dynamics and protective behaviors throughout the pandemic (3-5), they 54 also have the potential to shape variant history and the development of the immune landscape of the popu-55 lation. For example, an individual with low SES who was not able to social distance early in the pandemic 56 [4] might be more likely to have had an early-pandemic infection prior to the emergence of new variants. 57 On the other hand, a low SES individual is less likely to be vaccinated than a high SES counterpart [5]. 58 Yet socioeconomic status is still a commonly unrecognized axis of host heterogeneity in disease modeling 59

60 [16, 17].

Mathematical models can be wielded as a powerful tool for public health when host- and pathogen-level 61 data are plentiful, but an understanding of complex population-level dynamics is lacking [18]. Understand-62 ing booster impacts under the influence of population and pathogen heterogeneity can inform not only the 63 acquisition and implementation of booster vaccines but also shed light on future strategies for booster formu-64 lation. In this work, we synthesized serological measures of variant-specific immune history, socioeconomic 65 disparities, temporal vaccination trends, and broad variation of historical variant wave sizes to inform mod-66 els of transmission for three countries (India, Ecuador, and Malaysia) and evaluated possible landscapes of 67 immunity more broadly across low- and middle-income country (LMIC) settings. Using this immune his-68 tory, we forward-simulated the potential impacts of three formulations of bivalent or monovalent boosters 69 in two models with complementary strengths, in the context of diverse landscapes of immunity and varying 70 levels of pathogen immune escape or adaptation in infectiousness. 71

# 72 **Results**

# 73 Landscape of immunity

<sup>74</sup> In order to characterize the effect of variant-specific immunity on population-level booster impact, we iden-

<sup>75</sup> tified three discrete, historical waves of SARS-CoV-2 for our analysis - Wild-type (WT), Delta, and Omicron

- using India, Ecuador, and Malaysia as benchmark countries due to the diverse sizes of their variant waves

<sup>77</sup> (Figure S1). We first implemented a model that tracks the variant-specific immune history of individuals

<sup>78</sup> at each time-point, captures relative wave size for each country (Figure S2, Table S1), and incorporates the

observed temporal vaccination trends for each country and socioeconomic group (Figure S3, Table S2). We
 refer to this as the history-specific model or HSM, and under this model, an individual's risks of infection
 are explicitly influenced by their specific immune history and the currently circulating variant, while the
 infection fatality rate is influenced by immune history, socioeconomic status, and age (Figure 1A, Table S3).

Using the variant-specific immune histories of individuals tracked through historical simulations in the 83 HSM, we explored the possible immune landscapes over time for the three countries prior to a booster 84 intervention (Figure 1B) and inferred the prevalence of each history type prior to the time of boosting at 85 28 months (Figure S4). Our findings suggest that India had the highest share of naive individuals, with 86 an average of 7.8% of the population having never been infected or vaccinated. Their vaccine-only pop-87 ulation was also high (40.9%) compared to Ecuador (23.1%) and Malaysia (10.9%). Yet, despite having 88 lower natural exposure overall, our simulations indicate that India carried by far the highest percentage of 89 'Delta' and 'Delta + vaccine' histories, at values of 5.6% and 19.4% respectively. In Malaysia, 'Delta' 90 exposures appeared to be less common, but there was a much higher presence of 'Omicron' histories than 91 in India (3.0% for 'Omicron' and 24.3% for 'Omicron + vaccine'). A pattern similar to that of Malaysia 92 was present in Ecuador, where Omicron histories were also more prevalent than Delta or WT. We used 93 these diverse immune histories, particularly in comparing vaccine-only versus hybrid immunity, to assess 94 the population-level of protection from a booster intervention under varying hypotheses of individual-level 95 efficacy. 96

#### 97 Impact of booster formulation on disease incidence and deaths

98 We introduced booster vaccines at 28 months under three formulations - bivalent (WT + Omicron), mono-

valent (WT), and a hypothetical monovalent (Omicron) - and considered two possible scenarios of pathogen

<sup>100</sup> infectiousness (Table S3): one that is conservative (110% relative to Omicron) and another that more closely

<sup>101</sup> resembles previous increases in the observed secondary attack rate (SAR) between variants (130% relative



Figure 1: Landscapes of immunity from the history-specific model (HSM). (A) Level of protection from severe disease by immune history and variant wave, estimated using neutralizing antibody titers in human sera [19, 20]. Lengths 2, 3, and 4+ represent permutations of immune history that were not explicitly tracked (e.g. 'WT + Delta + Omicron'). (B) Average immune history trajectories of 500 runs informed by historical incidence data from Ecuador, India, and Malaysia shown in Figure S1 [21]. Simulations of the prevalence of histories are shown until day 839, one day before booster vaccinations are implemented at 28 months. The infections over time for each country are shown in Figure S2. General simulation parameters are shown in Table S3, with country-specific population structure in Table S4, contact rates by country and SES in Table S5, wave- and country-specific stringency in Table S1, and vaccination parameters by country and SES in Table S2. The HSM compartmental diagram is shown in Figure S5.

to Omicron), considering that the SAR for Delta was  $\sim 60\%$  higher than early-pandemic estimates and the 102 SAR for Omicron was  $\sim 40\%$  higher than for Delta [7]. To model protection conferred by these boosters, 103 we considered a 'history-dependent' scenario where the impact of each formulation is based on an indi-104 vidual's prior exposure, and calculated relative to history-specific responses to primary series vaccination 105 (Figure S6). At 30 months, we introduced the Omicron\* variant and updated history-specific immunity for 106 both boosted and unboosted individuals (Figures 1A, 2A). Unsurprisingly, our results show that boosting 107 always reduced cases (Figure 2B) and disease-related deaths (Figure 2C) in all three countries during this 108 new wave, regardless of formulation. For example, in the 130% infectiousness scenario, wave peaks with 109 boosting were 22-37% lower than the peak with no boosting in India, 33-39% in Ecuador, and 44-45% in 110 Malaysia. The smaller reduction observed in India may be attributable to a lower boosting rate (Figure S3) 111 and the distinct immune landscape compared to Malaysia and Ecuador (Figure 1B). 112

In order to quantify the difference in deaths averted during the Omicron\* wave across booster formulations 113 (Figure 2C), we estimated the relative benefit of switching from monovalent (WT) to monovalent (Omicron) 114 or to bivalent (Equation 1) specific to each country and scenario. Values < 1 represent a net loss in deaths 115 averted from changing booster formulations, whereas values > 1 represent that the new formulation averts 116 more deaths than the previous formulation. If the benefit of switching from monovalent (WT) to a different 117 formulation is greater than the original benefit of implementing the monovalent (WT), then the relative ben-118 efit will be greater than 2. Therefore, if the relative benefit is in the interval (1, 2), then the new formulation 119 is still optimal to the monovalent (WT) booster in the given scenario, but the effect of boosting on the deaths 120 averted is stronger than the effect of booster formulation. 121

When comparing the relative benefit of switching to monovalent (Omicron), India was the only country 122 that would slightly benefit from this hypothetical booster, represented by values greater than 1.0 in both the 123 110% and 130% more infectious scenarios (Table S6). This marginal benefit in India may be attributable to 124 the high prevalence of Omicron histories in Ecuador and Malaysia compared to India, where Delta histories 125 appeared to be more prevalent (Figure 1B). When looking at the case of bivalent boosters, we found that 126 in the 110% infectiousness scenario, the relative benefit of bivalent boosters was 1.12, 1.18, and 1.66, for 127 Malaysia, Ecuador, and India, respectively. For the 130% infectiousness scenario, the relative benefit of 128 bivalent boosters was 1.09 for Malaysia, 1.12 for Ecuador, and 1.77 for India (Table S6). 129

This surprising finding - that switching formulations from monovalent (WT) to bivalent in a given sce-130 nario always yielded diminishing returns on the deaths averted with relative benefit values less than 2.0 -131 was consistent even in scenarios with conservative booster rollout speed (Figures S3E, S7, Table S7), and 132 in scenarios where booster curves for all countries match the superior rollout trajectory seen in Malaysia 133 (Figure S8, Table S7). In order to isolate the effects of the boosters, the main results show findings when 134 primary-series vaccination is stopped at the end of the Omicron wave. When we relaxed this assumption 135 by continuing primary series vaccination through Omicron\*, we found that this did not cause the relative 136 benefit of the bivalent to surpass 2.0 (Figures S3C, S9, Table S7). Finally, while our history-specific booster 137 scenarios were informed by responses to primary series vaccination, they were hypothetical. We therefore 138 tested two additional scenarios for booster efficacy: (1) same efficacy, where all individuals received the 139 same numeric change in protection from a given booster (Figure S10), and (2) same endpoint, where all 140 individuals reached the same end level of protection from boosting (Figure S11). The conclusion about the 141 relative benefit of bivalent boosters remained consistent (Table S7). 142

Infections during Omicron\* – History specific model



Figure 2: HSM booster parameters and projections during the Omicron\* period. (A) Booster protection against severe disease during the Omicron\* wave, by immune history, under a bivalent, WT monovalent, or hypothetical Omicron monovalent formulation. (B) Infection trends under three boosters or a no-boosting scenario based on the characteristics of Ecuador, India, and Malaysia. We simulated two scenarios of infectiousness where Omicron\* is 10% or 30% more infectious than Omicron. 95% confidence intervals from the t-distribution are shown (ribbons). (C) Deaths averted by boosting since the start of Omicron\* (30 months) through the end of simulations, under each booster. 95% confidence intervals from the t-distribution are shown with whiskers. Boosting parameters, which are assumed to be 10 weeks faster than for primary series vaccination, are shown in Table S8.

#### **143 Beyond country-specific trajectories**

Booster scenarios - History specific mode

в

In order to explore a wider range of scenarios that capture the relative influence of preexisting immunity 144 and degree of overlap with the currently circulating variant, we implemented a complementary and flexible 145 model, which we call the hybrid-immunity model (HIM). The HIM is a compartmental model that tracks 146 prior infection (none, one or more; not variant-specific), vaccine history (none, primary series, primary 147 series+booster), and simulates expected cases and deaths during the Omicron\* wave. For the three bench-148 marking countries, the level of cross-protection, prior infection, and baseline transmission rates expected are 149 parameterized based on the outputs of the history-specific model prior to boosting (Figures 1B, S4, Table 150 S1, S9). Country-specific booster trends are also matched (Figure S12). This allowed us to compare the 151 predictions between the two models for the benchmarked countries. We then used the hybrid immunity 152 model to vary these dimensions of immunity and to more thoroughly explore how booster impacts might 153 be influenced by prior population infection and the degree of cross protection conferred by natural infec-154 tion. To determine prior infections and cross protection at the start of the HIM simulations on day 900, we 155 used immune history distributions from day 899 in the HSM under a no-boosting scenario (Figure S13); 156 these may overestimate the cross protection, but because there is limited booster impact on the number of 157 infections during the window from day 839 to 899 (Figure S2), this is a close approximation. 158

In general, projections of infections during Omicron\* for the three countries were qualitatively similar for the HIM compared with the HSM, with similar outbreaks (Figure 3A). For the 110% infectiousness scenario,

the HIM predicted small outbreaks in the three countries. All three countries experienced outbreaks in the 161 130% infectiousness scenario, with the biggest peaks in Malaysia and India. Boosting reduced the size of the 162 Omicron\* wave across all three countries, with bivalent boosters having a stronger impact than monovalent 163 boosters. However, similar to the HSM, the impact of vaccine formulation was small. When looking at 164 deaths across the three countries, models revealed substantial differences across countries in the potential for 165 booster impacts, with India having by far the highest number of deaths with or without boosting, matching 166 the HSM (Figures S14, S15). This split in deaths across countries was larger overall in the HIM than in the 167 HSM, and additionally, the HIM predicted smaller outbreaks for Malaysia than the HSM. As a result India 168 was predicted to have the strongest potential benefit of boosting on deaths averted per 10,000 (Figures 3B 169 (black dots), S16, Table S11). Like the HSM, these findings from the HIM were similar in the conservative 170 booster rollout case (Figures S16, S17), but overall deaths were higher with slower booster rollout (Figure 171 S14). We also tested scenarios where boosting started at the beginning of the Omicron\* wave (Figure S18), 172 with similar findings but lower deaths averted overall (Figures S19, S20). 173



Figure 3: HIM projections. (A) Infections per 10,000 during the Omicron\* period, where Omicron\* is considered to be 10% or 30% more infectious than Omicron. (B) Deaths averted per 10,000 under a bivalent or monovalent booster, compared to a 'no boosting' scenario. Prior immunity represents the percentage of the population that has been previously infected. Cross protection represents the overlap between the population's immune history and the currently circulating variant. Country-specific immunity levels are included (black dots). The HIM model structure is shown in Figure S5. General parameters are shown in Table S3, stringency in Table S1, initial conditions in Table S10, cross-protection in Table S9, and boosting parameters in Table S8.

#### 174 Consequences of immune escape and cross protection in diverse immunity contexts

Broader sweeps across the immune landscape using the HIM revealed that the similarity between monova-175 lent and bivalent booster performance was largely determined by population immunity (Figure 3B, Figure 4). 176 Generally, the gains from implementing a bivalent booster were most pronounced at low levels of popula-177 tion immunity, but absolute differences remained relatively small for all parameter values considered. The 178 difference between monovalent and bivalent vaccination was smallest at high levels of cross protection and 179 prior exposure (as was seen in the three benchmarking countries), and diverged more as the protection from 180 natural infection decreased across both dimensions. For example, in Malaysia, the HSM estimated that 181 90.7% of the population had been infected by the start of Omicron\* and that this protection conferred a 182 72.8% protection against disease-related death (Table S9). At that preexisting immunity level in a 130% 183 infectiousness scenario, monovalent boosting was expected to avert 0.14 deaths per 10,000 compared with 184 0.22 deaths per 10,000 in the bivalent vaccination scenario, representing that the additional gain in deaths 185 averted from jumping to an improved formulation (0.08) is just over half of what was gained when mov-186 ing from no-boosting to monovalent - a relative benefit of 1.57 (Equation 1, Figure 4). These diminishing 187 returns account for much of the high-immunity parameter space. However, in the absence of any baseline 188 immunity, bivalent boosting could avert 3.4 deaths per 10,000 compared with 0.6 deaths per 10,000 in the 189 monovalent case. This gain of 2.8 deaths averted per 10,000 by improving formulations, compared to 0.6 190 gained by simply boosting, represents a relative benefit of 5.67. In the other countries, diminishing returns 191 accounted for a wider swath of the parameter space (Figure 4). In general, at hypothetical lower levels of 192 immunity, Malaysia was predicted to have higher impacts than the other countries (Figure 3B), reflecting 193 that booster curves for Malaysia were superior (Figure S12). Whereas the total deaths averted were similarly 194

sensitive to both the cross protection and prior infections (Figure 3B), the prevalence of prior infection was



Figure 4: Comparison of bivalent vs. monovalent boosters in the HIM. Relative benefit of the bivalent booster is calculated with Equation 1, matching the HSM. Grey values represent high-immunity areas where zero deaths were averted by a monovalent booster and thus Equation 1 cannot be calculated. Prior immunity represents the percentage of the population that has been previously infected. Cross protection represents the overlap between the population's immune history and the currently circulating variant. Country-specific immunity levels are included (black dots).

Country	SAR	Booster	Match HSM	Adjust Transmission	Transmission Recalibrated
Ecuador	110%	Monovalent	0.07	0.3	0.57
	110%	Bivalent	0.11	0.94	0.84
	130%	Monovalent	0.27	0.24	0.59
	130%	Bivalent	0.38	0.88	1.02
India	110%	Monovalent	0.4	0.13	0.67
	110%	Bivalent	0.57	0.61	1.14
	130%	Monovalent	0.58	0.1	0.43
	130%	Bivalent	0.96	0.58	0.9
Malaysia	110%	Monovalent	0.06	0.32	0.45
	110%	Bivalent	0.11	1	0.6
	130%	Monovalent	0.14	0.28	0.57
	130%	Bivalent	0.22	1	0.86

Table 1: Comparison of HIM deaths per 10,000 across three scenarios: (1) Matching the HSM (column 4; as shown in Figures 3 and 4) (2) Removing the reduction in transmission for people with pre-existing immunity (column 5), and (3) Removing the transmission reduction but recalibrating  $\beta$  to remain consistent with Omicron [23] (column 6).

<sup>196</sup> the greatest determining factor in whether a bivalent booster would be optimal.

The HSM and HIM both assumed that individuals with pre-existing immunity have strongly reduced infec-197 tiousness based on [22], but this may not always be the case, particularly as new variants emerge. We thus 198 tested an additional scenario in the hybrid immunity model where prior exposure or immunization had no 199 impact on host infectiousness during the Omicron\* wave, under two parameterizations. First, we left all 200 other parameters related to the force of infection unchanged, including the baseline risk of infection given 201 contact, but removed all transmission-reducing effects during Omicron\* so that the effective infectious pro-202 portion is equal to the total infectious proportion. In this extreme scenario, all three countries experienced 203 large waves regardless of whether the baseline infectiousness for Omicron\* was 10% or 30% greater than 204 Omicron (Figure S21). Under these conditions, it was almost always optimal to implement a bivalent booster 205 (Figure S22). However, stringency in the HSM and HIM was calibrated to observed wave sizes for Omicron 206 with the assumption of transmission-reducing immunity, so this scenario represents an extreme jump in the 207 overall force of infection. We therefore ran an additional analysis where the overall force of infection was 208 re-calibrated to fit the  $R_0$  of Omicron (Table S3) without transmission-reducing effects (Figures S23, S24). 209 In this scenario, cases were still increased but the relative benefit of bivalent boosting was less than 2.0 210 in most of the high-immunity parameter space, and in all but one country-specific scenario (India, 130%) 211 more infectious). In general, HIM-projected deaths tended to be lower than the HSM across sensitivity 212 analyses (Figures S14, S25, S26) - except in the case where transmission structure was adjusted but  $\beta$  was 213 not recalibrated (Figure S27) - reflecting differences in the structure of immunity; the HSM is designed to 214 capture more complex dynamics of immunity over time, number, and type of exposures, whereas the HIM 215 tracks recent recovery (sterilizing immunity) and tiers of susceptibility depending on vaccination status and 216 infection-naive versus previously infected. This was also reflected in the scale of the deaths averted which 217 were generally lower across scenarios (Table 1). 218

Finally, in the HIM, we assume that 50% of individuals with prior infection start in the recovered (R) compartment due to the short interval between transmission waves. The remainder start in the susceptible but previously infected compartment. This assumption is roughly consistent with most of current population

immunity having been gained during the Omicron wave (like in Malaysia and Ecuador), of which roughly half would have waned at the start of the Omicron\* wave. Thus, at very high levels of prior immunity, a substantial fraction of the population cannot be reinfected until waning occurs, which could influence our estimates of booster impact. Additionally, this assumption may be less realistic for India, which experienced a larger Delta wave than Omicron (Figures S1, S2). As a sensitivity analysis, we re-ran our model assuming that only 25% of individuals with prior infection start in the R compartment. While cases and deaths were

higher (Figures S28A, S29), the overall findings were unchanged (Figures S28, S30).

# **Discussion**

The continued emergence of new variants of SARS-CoV-2 poses a challenge for maintaining effective 230 vaccine-induced immunity in the population. As individuals continue to acquire diverse immune histo-231 ries that confer highly varied protection against newer variants [8], understanding the impact of old and 232 new vaccine formulations in populations with varying exposure histories is crucial. We found that at the 233 population level, particularly in the current context where population immunity is high, it is more impor-234 tant that a booster is implemented, than whether that booster is bivalent or monovalent. Strikingly, this 235 was largely consistent across all three countries in both models, even in scenarios where rollout speed was 236 conservative or an emerging variant was highly transmissible. While bivalent boosters showed a greater 237 benefit when the rate of previous SARS-CoV-2 infections was low, those scenarios are unlikely for most 238 countries. For example, a meta-analysis found that the rate of infection-induced seroprevalence in India 239 may have been higher than 50% by the third quarter of 2021 [24], a year before bivalent boosters became 240 available. In Malaysia, estimates from reported cases and age-stratified case fatality rates suggest that ap-241 proximately 33% of individuals had been infected by December 2021, with only 23% of cases estimated to 242 be reported [25]. Infection-induced seroprevalence estimates for a selection of European low- and middle-243 income countries (LMICs) had surpassed 50% by as early as November 2020 [24]. The continued benefit 244 of the original monovalent boosters in these contexts is an encouraging finding, especially given that it may 245 not be economically viable for an LMIC to acquire an entirely new vaccine stock. Still, care should be taken 246 in interpreting the effect size of formulation across countries with varying population sizes, since 1 death 247 averted per 10,000 is a larger absolute number in India than in Ecuador. Policymakers should consider the 248 balance between relative and absolute gains when deciding which formulation to implement. 249

Monovalent boosters targeting the most recently circulating variant did not perform better than WT mono-250 valent formulations in populations with a high degree of natural exposure. Red Queen dynamics [26] as 251 well as documented imprinting effects [8] may give rise to an endless race to capture the newest variant 252 match. While exploring boosters that directly target emerging variants is beyond the scope of this study, this 253 has been the case for influenza virus. Influenza vaccine development and strain selection are based on what 254 might be circulating during the upcoming season - informed by predictive models [27, 28] - and there can be 255 severe impacts on vaccine efficacy if expectations do not align with reality [27]. In the face of this, a possible 256 future direction for SARS-CoV-2 to make population-level gains in immunity is the development of pan-257 sarbecovirus or pan-coronavirus vaccines that induce broad cross-reactivity [29, 30]. Indeed, experimental 258 work is already underway that supports this goal, but with a potentially long road ahead [29, 30]. 259

Several additional factors should be considered when interpreting the findings of this paper. First, this work was conducted in response to a call from the World Health Organization in August 2022, and therefore our models and assumptions were built between 2022 and 2023. During a new variant wave, assumptions on the force of infection, rate of booster uptake, level of immune escape, and other factors are exploratory and

hypothetical. We acknowledge that our simulations of Omicron\* may be different from currently circulating 264 variants and newly available boosters, but exploring post-Omicron lineages is beyond the scope of this 265 study. Second, while neutralizing antibody titers allowed us to parameterize variant-specific protection in 266 a way that could not be done with existing clinical trial data, and correlation with protection has been 267 previously suggested for SARS-CoV-2 [31], we acknowledge that titers may not always be a good correlate 268 of protection in all cases (e.g. [32]). Conversely, in the hybrid-immunity model, the impacts of a booster 269 might be underestimated by using generalized booster efficacy and not accounting for the specific type of 270 hybrid immunity. Third, while we chose three countries with distinct parameterizations to calibrate these 271 models, fitting our models to data is challenging due to the difficulties of fitting individual-based models 272 and incorporating individual immune trajectories to compartmental models. While our results are therefore 273 more qualitative, they still match the patterns observed in incidence data. 274

When comparing the two models, the hybrid-immunity model might produce lower estimates of incidence 275 and deaths than the history-specific model for several reasons - for example, the inclusion of age-specific 276 contact rates (which are lower for older adults), reduced specificity of immune histories, and because im-277 munity acquired during the current wave is likely to be stronger than pre-existing immunity, causing the 278 cross-protection achieved by natural infection to change gradually over time during the Omicron\* wave for 279 the HSM but is fixed for the HIM. Deaths averted predicted by the HIM might also be lower than the HSM 280 because booster vaccination does not confer even short term sterilizing immunity and only reduces prob-281 ability of infection and severe disease for future exposures. While we acknowledge the limitations of our 282 study, the outcomes of the two models presented here are consistent when evaluating the relative benefit of 283 booster formulation and we are confident that the qualitative findings of relative booster impacts are robust. 284

In summary, incorporating numerous sources of host heterogeneity across diverse settings and alternative model structures has enabled us to quantify the relative impact of boosting compared to booster formulation. We have demonstrated a consistent finding that in some places, the original generation of SARS-CoV-2 monovalent boosters can still avert a similar number of deaths to the bivalent, without requiring the acquisition of a new vaccine stock. These results have potential implications for future vaccine policy and development.

# 291 Methods

## 292 History-specific model (HSM)

#### 293 Immune histories

We projected previously reported data - neutralizing antibody titers from human sera which were stratified by immune history [19, 20] - onto a scale from 0.05-0.95, with larger numbers representing higher protection against SARS-CoV-2 (Figure 1A). Unvaccinated titers were those from individuals with no prior vaccine doses, and vaccinated titers were those from individuals with 2 or more doses (fully vaccinated).

The base probabilities of (1) being infected after contact and (2) dying due to infections are scaled down based on these wave- and history-specific parameters. This allowed us to parameterize single-infection histories as well as hybrid histories for the WT, Delta, and Omicron waves. For individuals with 2 prior infections, which was not accounted for in this data, we took an average of the 'strain + vaccine' serotypes for each wave. For four or more immune history events, we assumed a protection parameter of 0.05 (95%). For three history events (three infections or two infections + vaccine), we assumed the protection would

fall halfway between 2 events and 4+ events for each wave. Finally, we constructed an Omicron\* wave by drifting protection down by 0.10 for all groups, equal to the change in protection moving from the WT wave to Delta. Individuals with 'Omicron\*' or 'Omicron\* + vaccine' histories are given protection equal to what 'Omicron' and 'Omicron + vaccine' have during the Omicron wave.

#### 308 Model structure

We implemented a stochastic, individual-based transmission model in Python. This model spans a period 309 of three years, through 4 discrete waves of SARS-CoV-2 variants: WT (beginning in March 2020), Delta, 310 Omicron, and a hypothetical Omicron lineage called Omicron\* which we modeled to begin transmitting in 311 October 2022. Each wave has a distinct risk of infection given contact, estimated from household secondary 312 attack rates [7]. The simulated populations are grouped into children (0-20), adults (21-65), and elderly 313 (older than 65) whose proportions reflect the age structure of each country [33], with 50% being high SES 314 and 50% low SES. To capture relative waves sizes for each country, we implemented a stringency index with 315 a value for each wave (Table S1). We ran 500 replicates for each set of simulation parameters. Simulations 316 progress though a modified tau-leap algorithm [34]. General parameters are shown in Tables S3. 317

Country-specific, SES-stratified contact rates in this model are estimated from pre-pandemic contact data 318 for each country [35] combined with estimates of unequal mobility by SES during the pandemic [4] and the 319 tendency towards within-SES contact vs. across-SES [36, 37] (Table S5). Susceptible (S) individuals can 320 become exposed (E) through contact with an infectious individual (I). The probability of becoming exposed 321 given contact is stratified by variant-specific immune history. After exposure, they become infectious. The 322 probability that an infected individual will recover or die is stratified by age and SES [4], as well as variant-323 specific immune history. While recently recovered (R), an individual does not have sterilizing immunity, 324 but rather a peak level of protection dictated by their immune history (Figure 1A), which comes from neu-325 tralizing antibody titers in human sera [19, 20], and is order-agnostic. Recently recovered individuals have 326 a lower risk of infection and disease-related death than those in the susceptible class. Here, the protection 327 against infection is assumed to be 80% of the values shown in (Figure 1A) which apply to the risk of death 328 - reflecting evidence that in the early months after SARS-CoV-2 infection or vaccination, protection against 329 both severe disease and infection is high, but protection against infection is moderately lower [38]. After 330 recovery, individuals eventually wane into the susceptible class again, with a dampened immune history 331 protection parameter, and the amount of this dampening is dictated by their previous number of immune 332 exposures - with more exposure resulting in a lower degree of waning (Table S3). The incorporation of peak 333 (recently recovered class) and waned (susceptible class) protection as opposed to sterilizing immunity and 334 susceptibility reflects evidence that individuals are not fully protected against reinfection even when their 335 immune history is fresh [38]. This granularity in considering the peak and waned protection of an individual, 336 across immune histories, is a core strength of this model. 337

#### 338 Vaccination

SES-stratified vaccination is implemented from day 320 (during the WT wave, around January 2021) until the beginning of Omicron\*, according to the true rates observed for each country [5] (Figure S3, Table S2). Susceptible, exposed, and recently recovered individuals can be vaccinated - and if they are not already recently recovered, they move to the recently recovered class. We stopped primary series vaccination at the start of Omicron\* reflecting that a small number of primary series doses were projected to be given during Omicron\* (Fig. S3), and to isolate the effect of boosting from interference by the primary series vaccines.

#### 345 Boosting

Boosters function similarly to vaccination, but with faster timing and lower coverage (Figure S3, Table S8). Booster rollout was assumed to be 10 weeks faster than primary series vaccination, to reflect possible improvements in infrastructure (Figure S3D, Table S8). We assumed that the coverage of monovalent boosters in October 2023 represented a peak booster coverage level in the population [39]. Children and unvaccinated individuals are not eligible to receive a booster, reflecting booster eligibility at the time of the study.

Data on booster efficacy by variant-specific immune history and formulation are limited. We therefore used 351 the neutralizing titer data [19, 20] to project booster-related changes in the level of protection against se-352 vere disease, using responses to primary-series vaccination during the WT wave. Because Omicron\* is a 353 hypothetical variant with no data on primary series vaccination responses, we assumed that the change in 354 protection from boosting would be the same as for the Omicron variant. Bivalent boosters were assumed to 355 confer the same numeric change as monovalent vaccines did during the WT wave. We considered monova-356 lent boosters to have 40% of the efficacy of bivalent boosters against Omicron\* infection based on estimates 357 of efficacy against severe infection [40]. Because we started boosting two months prior to Omicron\*, there 358 was a two-month period when the bivalent and Omicron monovalent formulations were matched to the cur-359 rently circulating variant, but the WT monovalent was not. To account for this, during the Omicron wave we 360 increased the Omicron monovalent efficacy by 10 percentage points (the change in protection for all groups 361 when moving from the Omicron wave to Omicron\*) and bivalent protection by 5 percentage points (half of 362 what was applied for Omicron monovalent, because it contains both WT and Omicron) (Figure S6). 363

#### **364 Relative benefit**

Equation 1 quantifies the difference in booster benefit among different formulations, which we call the relative benefit.

Relative benefit 
$$(x,y) = \frac{\text{Deaths averted under y vaccine formulation}}{\text{Deaths averted under x vaccine formulation}}$$
 (1)

- <sup>367</sup> There are three key cases for the relative benefit:
- (i) If (and only if) [Booster y deaths averted] < [Monovalent (WT) deaths averted], then the relative ben-</li>
   efit of booster y is less than 1.0.
- (ii) If (and only if) [Booster y deaths averted] > [Monovalent (WT) deaths averted] and ([Booster y deaths averted] [Monovalent (WT) deaths averted]) < [Monovalent (WT) deaths averted], then the relative benefit is</li>
   between 1.0 and 2.0.
- (iii) If (and only if) [Booster y deaths averted] > [Monovalent (WT) deaths averted] and ([Booster y deaths averted] –
   [Monovalent (WT) deaths averted]) > [Monovalent (WT) deaths averted], then the relative benefit is
   greater than 2.0.
- In words, if the relative benefit is less than 1.0, then there is a net loss in the deaths averted when moving from WT monovalent to Omicron monovalent or bivalent. If the new formulation averts more deaths than monovalent (WT), but the gain moving from no-booster to a monovalent (WT) booster is larger than the gain from monovalent (WT) to a new formulation, then the relative benefit is between 1.0 - 2.0. Finally, if the new formulation both averts more deaths than monovalent (WT) and the gain moving from no-booster

to a monovalent (WT) booster is smaller than the gain from monovalent (WT) to a new formulation, then the relative benefit is greater than 2.0.

#### 383 Hybrid-immunity model (HIM)

#### 384 Model structure

We also implemented a compartmental transmission model in R which extended a published COVID-19 385 transmission model [41] to account for vaccine-specific (none, vaccinated, vaccinated + boosted), natural 386 (0, 1+ infection), and hybrid immunity (combination). Our SEIR-like model includes six infection com-387 partments: Susceptible S, Exposed E, Asymptomatic A, Symptomatic I, Recovered R, and Deceased D 388 (Figure S5). The model was also stratified by age ( $< 20, 20 - 64, and \ge 65$  years), socioeconomic status 389 (high vs. low), prior natural infection (no natural infection or one or more prior infection), and vaccine 390 status (unvaccinated, primary series, and boosted). Susceptible individuals become exposed through contact 391 with an infectious person (asymptomatic or asymptomatic), after which they enter a latent period (in the 392 exposed E class). After leaving the latent class, individuals develop either symptomatic or asymptomatic 393 infection. All asymptomatic individuals recover. Some symptomatic individuals recover, but some frac-394 tion dies. Those in the low socioeconomic group have higher mortality rates [4], higher transmission rates 395 because of differences in pandemic mobility [4], and slower rates of vaccine rollout [5] than their higher 396 income counterparts. General parameters are shown in Table S3. 397

#### 398 Natural infection

After recovery, individuals infected for the first time have sterilizing immunity for 300 days (10 months), 399 after which point they enter the susceptible class for individuals with prior infection  $(S_2)$ . Our main sim-400 ulations assume that 50% of those who have been infected previously have waned as of October 2022, 401 consistent with most natural immunity having been acquired during the omicron wave, but we consider an 402 alternative where 75% have waned as a sensitivity analysis. Individuals who have been previously infected 403 have a lower rate of infection (1 - 0.8cp) and mortality (1 - cp), which is influenced by the level of cross 404 protection (cp) between the prior infecting strains (based on the population-averaged immune history) and 405 the currently circulating strain. Upon re-infection, previously infected individuals can follow the same steps 406 as for the compartments in the base model. We only model two levels of infection, assuming that infectivity 407 and severity are similar for secondary and higher infections. The level of pre-existing immunity and cross 408 protection at the start of the Omicron\* wave was estimated for each country based on the population immune 409 history profiles from the history-specific model (Table S9). 410

#### 411 Vaccination

Primary series vaccination. Vaccination was implemented by adding additional compartments for vaccinated/vaccinated and boosted individuals, which mirror the compartments in the base model:  $S_V$ ,  $E_V$ ,  $A_V$ ,  $I_V$ ,  $R_V$ , and  $D_V$  for vaccination. We assumed that everyone who was planning to receive their primary vaccine series had already done so as of October 2022, so only booster vaccines were included in our main model simulations, matching the HSM. Baseline vaccine prevalence in October 2022 was set in the same was as the HSM, following published data from [5].

<sup>418</sup> Vaccine efficacy for the primary series was assumed to reduce the risk of mortality by 70%, consistent with <sup>419</sup> data on Astra-Zeneca protection after 6 months [42–45]. While primary series vaccination for Astra-Zeneca

can reduce risk of infection by about 50%, these benefits are only present shortly after vaccination [42–45].
Given that the populations included in our model completed their vaccine campaigns earlier and current

rollout rates are low, we do not model any protection against infection for the primary vaccination class.

Booster vaccination. To capture the potential for booster vaccination, we added additional compartments 423  $(S_B, E_B, A_B, I_B, R_B, \text{ and } D_B)$ . For simplicity, we assume that individuals in the S, E, or R classes 424 can be vaccinated but individuals in the other compartments will not be. To reflect the fact that coverage 425 of vaccine boosters was low in LMICs in October 2022, when HIM simulations began, only one boosted 426 class was used and its efficacy was varied to reflect the potential benefit of variant specific boosters. Booster 427 vaccination moves vaccinated individuals to the corresponding booster class, but does not confer specific 428 temporary immunity (unlike the HSM). In other words,  $S_V$  individuals move to the  $S_B$  class, not the  $R_B$ 429 class. Similar to the HSM, we only model adult boosting. We implemented vaccination using dynamic daily 430 rates using the same approach as the history-specific model (Table S8), where daily doses were administered 431 until coverage saturates at its peak level. We considered an optimistic roll out as our default scenario, where 432 the halfway week of the rollout curve was sped up by 10 weeks compared to primary series vaccination, but 433 also considered a conservative rollout as a sensitivity analysis where the speed of boosting matches primary 434 series vaccination (Table S2). 435

#### 436 Hybrid immunity

We also explicitly accounted for joint natural immunity and vaccine-derived immunity-individuals who 437 have both exposures are tracked in a vaccinated and infected classes  $(S_{V2}, E_{V2}, A_{V2}, I_{V2}, R_{V2}, \text{and } D_{V2})$ 438 or vaccinated and boosted classes ( $S_{B2}$ ,  $E_{B2}$ ,  $A_{B2}$ ,  $I_{B2}$ ,  $R_{B2}$ , and  $D_{B2}$ ) and their protection from both 439 exposures is modeled as multiplicative. For example, bivalent vaccination reduces risk of infection by 74%. 440 In Malaysia, cross protection from prior infection was estimated at 72.8%. Thus, an individual with both 441 exposures has an infection risk of  $(1 - 0.74) \times (1 - 0.73) \times \beta$  or a combined reduction in infection risk of 442 93%. We do not differentiate between the order of vaccination and natural infection in the hybrid immunity 443 model. 444

Booster vaccination can enhance protection against both infection  $(VE_i)$  and severe disease  $(VE_h)$ . We use scenarios consistent with the individual-based model bivalent booster efficacy  $(VE_i = 0.74, VE_h = 0.925)$  and monovalent booster efficacy  $(VE_i = 0.657, VE_h = 0.5256)$  in the main analysis. While this yields a lower efficacy against severe disease specifically for the monovalent booster  $(VE_h)$  compared with primary series vaccination, the total protection against severe disease is higher (84%) due to the inclusion of protection against infection.

# 451 Acknowledgements

This work was funded by the World Health Organization. The authors would like to thank the Biocluster at
 the Carl R. Woese Institute for Genomic Biology, University of Illinois Urbana-Champaign, for providing
 access to the computing resources.

## 455 **Competing interests**

<sup>456</sup> The authors declare that they have no competing interests.

#### 457 **Data and materials availability**

All codes and data necessary to evaluate the conclusions of the paper and reproduce the figures in the main text will be made available upon publication.

# 460 **References**

- [1] Ke R, Martinez PP, Smith RL, Gibson LL, Mirza A, Conte M, et al. Daily longitudinal sampling
   of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness. Nature microbiology.
   2022;7(5):640-52.
- [2] Lloyd-Smith JO, Schreiber SJ, Kopp PE, Getz WM. Superspreading and the effect of individual variation on disease emergence. Nature. 2005;438(7066):355-9.
- [3] Huang J, Kwan MP, Kan Z. The superspreading places of COVID-19 and the associated built environment and socio-demographic features: A study using a spatial network framework and
   individual-level activity data. Health & Place. 2021;72:102694.
- 469 [4] Mena GE, Martinez PP, Mahmud AS, Marquet PA, Buckee CO, Santillana M. Socioeco 470 nomic status determines COVID-19 incidence and related mortality in Santiago, Chile. Science.
   471 2021;372(6545):eabg5298.
- [5] Larsen SL, Shin I, Joseph J, West H, Anorga R, Mena GE, et al. Quantifying the impact of
  SARS-CoV-2 temporal vaccination trends and disparities on disease control. Science Advances.
  2023;9(31):eadh9920.
- [6] Riou J, Panczak R, Althaus CL, Junker C, Perisa D, Schneider K, et al. Socioeconomic position and
   the COVID-19 care cascade from testing to mortality in Switzerland: a population-based analysis. The
   Lancet Public Health. 2021;6(9):e683-91.
- [7] Madewell ZJ, Yang Y, Longini IM, Halloran ME, Dean NE. Household secondary attack rates of
   SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis.
   JAMA network open. 2022;5(4):e229317.
- [8] Suryawanshi R, Ott M. SARS-CoV-2 hybrid immunity: silver bullet or silver lining? Nature Reviews
   Immunology. 2022;22(10):591-2.
- [9] Tan CW, Chia WN, Zhu F, Young BE, Chantasrisawad N, Hwa SH, et al. SARS-CoV-2 Omicron variant emerged under immune selection. Nature Microbiology. 2022;7:1756-61.
- [10] Röltgen K, Nielsen SC, Silva O, Younes SF, Zaslavsky M, Costales C, et al. Immune imprinting,
   breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and
   vaccination. Cell. 2022;185(6):1025-40.
- [11] Wheatley AK, Fox A, Tan HX, Juno JA, Davenport MP, Subbarao K, et al. Immune imprinting and
   SARS-CoV-2 vaccine design. Trends in Immunology. 2021;42(11):956-9.
- [12] Gostic KM, Ambrose M, Worobey M, Lloyd-Smith JO. Potent protection against H5N1 and H7N9
   influenza via childhood hemagglutinin imprinting. Science. 2016;354(6313):722-6.

- [13] Oidtman RJ, Arevalo P, Bi Q, McGough L, Russo CJ, Cruz DV, et al. Influenza immune escape under
   heterogeneous host immune histories. Trends in Microbiology. 2021;29(12):1072-82.
- <sup>494</sup> [14] Lv H, So RT, Teo QW, Yuan M, Liu H, Lee CCD, et al. Neutralizing Antibody Response to Sarbe-<sup>495</sup> covirus Is Delayed in Sequential Heterologous Immunization. Viruses. 2022;14(7):1382.
- [15] Lin CY, Wolf J, Brice DC, Sun Y, Locke M, Cherry S, et al. Pre-existing humoral immunity to human
   common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response. Cell
   host & microbe. 2022;30(1):83-96.
- [16] Zelner J, Naraharisetti R, Zelner S. Invited commentary: to make long-term gains against infection
   inequity, infectious disease epidemiology needs to develop a more sociological imagination. American
   Journal of Epidemiology. 2023:kwad044.
- [17] Tizzoni M, Nsoesie EO, Gauvin L, Karsai M, Perra N, Bansal S. Addressing the socioeconomic divide
   in computational modeling for infectious diseases. Nature Communications. 2022;13(1):2897.
- [18] Heesterbeek H, Anderson RM, Andreasen V, Bansal S, De Angelis D, Dye C, et al. Modeling infectious
   disease dynamics in the complex landscape of global health. Science. 2015;347(6227):aaa4339.
- [19] Manali M, Bissett LA, Amat JA, Logan N, Scott S, Hughes EC, et al. SARS-CoV-2 evolution and
   patient immunological history shape the breadth and potency of antibody-mediated immunity. The
   Journal of infectious diseases. 2023;227(1):40-9.
- [20] Suryawanshi RK, Chen IP, Ma T, Syed AM, Brazer N, Saldhi P, et al. Limited cross-variant immunity
   from SARS-CoV-2 Omicron without vaccination. Nature. 2022;607(7918):351-5.
- 511 [21] WHO Coronavirus (COVID-19) Dashboard; https://covid19.who.int/.
- [22] Jung J, Kim JY, Park H, Park S, Lim JS, Lim SY, et al. Transmission and Infectious SARS CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated Individuals. JAMA Network Open.
   2022;5(5):e2213606-6.
- 515 [23] Burki TK. Omicron variant and booster COVID-19 vaccines. Lancet Respiratory Medicine. 516 2022;10(2).
- [24] Bergeri I, Whelan MG, Ware H, Subissi L, Nardone A, Lewis HC, et al. Global SARS-CoV-2 sero prevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized
   population-based studies. PLoS medicine. 2022;19(11):e1004107.
- [25] Jayaraj VJ, Ng CW, Bulgiba A, Appannan MR, Rampal S. Estimating the infection burden of COVID 19 in Malaysia. PLOS Neglected Tropical Diseases. 2022;16(11):e0010887.
- 522 [26] Van V. A new evolutionary law. 1973.
- [27] Morris DH, Gostic KM, Pompei S, Bedford T, Łuksza M, Neher RA, et al. Predictive modeling of
   influenza shows the promise of applied evolutionary biology. Trends in microbiology. 2018;26(2):102 18.
- [28] Agor JK, Özaltın OY. Models for predicting the evolution of influenza to inform vaccine strain selection. Human vaccines & immunotherapeutics. 2018;14(3):678-83.

- [29] Cankat S, Demael M, Swadling L. In search of a pan-coronavirus vaccine: next-generation vaccine
   design and immune mechanisms. Cellular & Molecular Immunology. 2023;21:103-18.
- [30] Tan CW, Valkenburg SA, Poon LL, Wang LF. Broad-spectrum pan-genus and pan-family virus vac cines. Cell Host & Microbe. 2023;31(6):902-16.
- [31] Khoury DS, Schlub TE, Cromer D, Steain M, Fong Y, Gilbert PB, et al. Correlates of protection,
   thresholds of protection, and immunobridging among persons with SARS-CoV-2 infection. Emerging
   Infectious Diseases. 2023;29(2):381.
- [32] Dimeglio C, Migueres M, Bouzid N, Chapuy-Regaud S, Gernigon C, Da-Silva I, et al. Antibody titers
   and protection against Omicron (BA. 1 and BA. 2) SARS-CoV-2 infection. Vaccines. 2022;10(9):1548.

[33] Population estimates and projections for 227 countries and areas.; 2022. https://www.census.
 gov/data-tools/demo/idb/#/pop?COUNTRY\_YEAR=2022&COUNTRY\_YR\_ANIM=
 2022&FIPS\_SINGLE=EC&FIPS=EC&popPages=BYAGE&POP\_YEARS=2022&menu=
 popViz.

- [34] Cao Y, Gillespie DT, Petzold LR. Avoiding negative populations in explicit Poisson tau-leaping. The
   Journal of chemical physics. 2005;123(5):054104.
- [35] Prem K, Cook AR, Jit M. Projecting social contact matrices in 152 countries using contact surveys
   and demographic data. PLOS Computational Biology. 2017;13:e1005697.
- [36] Yechezkel M, Weiss A, Rejwan I, Shahmoon E, Ben-Gal S, Yamin D. Human mobility and poverty as
   key drivers of COVID-19 transmission and control. BMC public health. 2021;21(1):1-13.
- [37] Bokányi E, Juhász S, Karsai M, Lengyel B. Universal patterns of long-distance commuting and social assortativity in cities. Scientific reports. 2021;11(1):1-10.

[38] Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, et al. Protective effectiveness of previous SARS CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic
 review and meta-regression. The Lancet Infectious Diseases. 2023.

- 552 [39] in Data O. Coronavirus (COVID-19) Vaccinations;. Available from: https:// ourworldindata.org/covid-vaccinations.
- [40] Lin DY, Xu Y, Gu Y, Zeng D, Wheeler B, Young H, et al. Effectiveness of bivalent boosters against
   severe omicron infection. New England Journal of Medicine. 2023;388(8):764-6.
- [41] Kraay ANM, Gallagher ME, Ge Y, Han P, Baker JM, Koelle K, et al. The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2. Journal of the Royal Society Interface. 2022;19:20220477.
- [42] Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine Effective ness against the Omicron (B.1.1.529) Variant. New England Journal of Medicine. 2022;386(16):1532 46.
- [43] Zeneca A. COVID-19 Vaccine AstraZeneca Real-World Evidence Summary;. Available
   from: https://www.astrazeneca.com/content/dam/az/covid-19/media/
   factsheets/COVID-19\_Vaccine\_AstraZeneca\_Real-World\_Evidence\_
   Summary.pdf.

566 567 568 569 570	[44]	Zeneca A. Boosting with AstraZeneca's vaccine provides high protection against Omicron, equivalent to mRNA COVID-19 vaccines;. Available from: https: //www.astrazeneca.com/country-sites/thailand/press-releases/ boosting-with-astrazenecas-vaccine-provides-high-protection-against-omicron- html.						
571 572 573	[45]	Solante R, Alvarez-Moreno C, Burhan E, Chariyalertsak S, Chiu NC, Hwang KP, et al. Expert Review of Global Real-World Data on COVID-19 Vaccine Booster Effectiveness Safety During the Omicron-dominant Phase of the Pandemic. Research Square. 2022;22(1):1-16.						
574 575	[46]	] Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino C, Hasell J, et al. Coronavirus Pandemic (COVID-19). Our World in Data. 2020. Https://ourworldindata.org/coronavirus.						
576 577 578	[47]	Murhekar MV, Bhatnagar T, Selvaraju S, Saravanakumar V, Thangaraj JWV, Shah N, et al. SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey. Lancet Global Health. 2021;59:E257-66.						
579 580	[48]	Megasari NLA, Utsumi T, Yamani LN, Juniastuti, Gunawan E, Furukawa K, et al. Seroepidemiological study of SARS-CoV-2 infection in East Java, Indonesia. Plos one. 2021;16(5):e0251234.						
581 582 583	[49]	Acurio-Páez D, Vega B, Orellana D, Charry R, Gómez A, Obimpeh M, et al. Seroprevalence of SARS-CoV-2 Infection and Adherence to Preventive Measures in Cuenca, Ecuador, October 2020, a Cross-Sectional Study. Int J Environ Res Public Health. 2021;18:4657.						
584 585	[50]	Wu Y, Kang L, Gao Z, Liu J, Liu M, Liang W. Incubation Period of COVID-19 Caused by Unique SARS-CoV-2 Strains: A Systematic Review and Meta-analysis. JAMA Network Open. 2022;5(8).						
586 587 588	[51]	Jung CY, Park H, Kim DW, Choi YJ, Kim SW, Chang TI. Clinical characteristics of asymptomatic patients with COVID-19: a nationwide cohort study in South Korea. International Journal of Infectious Diseases. 2020;99:266-8.						
589 590	[52]	CDC. COVID-19 Pandemic Planning Scenarios; 2020. Available from: https://www.cdc.gov/ coronavirus/2019-ncov/hcp/planning-scenarios.html#box1.						
591 592 593	[53]	Subramanian R, He Q, Pascual M. Quantifying asymptomatic infection and transmission of COVID- 19 in New York City using observed cases, serology, and testing capacity. Proceedings of the National Academy of Sciences. 2021;118(9):e2019716118.						

- <sup>594</sup> [54] Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of
   <sup>595</sup> SARS-CoV-2 through the postpandemic period. Science. 2020;368(6493):860-8.
- [55] Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Grifoni CEF, et al. Immunological memory to SARS CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529).
- [56] Altawalah H. Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination.
   Vaccines (Basel). 2021;9(8).